crestor patent expiration
The substance patent for Crestor expires on January 8, 2016, but AstraZeneca won a six-month extension under the US paediatric trials incentive programme.Sales of Actavis' generic before the extension expires on July 8 will incur a 39 per cent royalty fee to AstraZeneca.ctavis (formerly Watson Pharma) filed for approval of generic versions of AstraZeneca's product based on rosuvastatin calcium and rosuvastatin zinc and as a result of the settlement will now be able to sell its products on an exclusive basis in the US between May 2 and July 8, 2016.